Luengo-Gil G, Conesa-Zamora P. Potential Utility of Induced Translocation of Engineered Bacteria as a Therapeutic Agent for Mounting a Personalized Neoantigen-Based Tumor Immune Response. Glob Chall. 2021 Dec 16;6(3):2100051. doi: 10.1002/gch2.202100051. eCollection 2022 Mar. PubMed PMID: 35284089; PubMed Central PMCID: PMC8902290.
AÑO: 2022; IF: 5.135
|
Asensi-Canto A, Lopez-Abellan MD, Castillo-Guardiola V, Hurtado AM, Martinez-Penella M, Luengo-Gil G, Conesa-Zamora P. Antitumoral Effects of Tricyclic Antidepressants: Beyond Neuropathic Pain Treatment. Cancers (Basel). 2022 Jul 1;14(13):3248. doi: 10.3390/cancers14133248. PubMed PMID: 35805019; PubMed Central PMCID: PMC9265090.
AÑO: 2022; IF: 6.575
|
Alburquerque-Gonzalez B, Lopez-Abellan MD, Luengo-Gil G, Montoro-Garcia S, Conesa-Zamora P. Design of Personalized Neoantigen RNA Vaccines Against Cancer Based on Next-Generation Sequencing Data. Methods Mol Biol. 2022;2547:165-185. doi: 10.1007/978-1-0716-2573-6_7. PubMed PMID: 36068464.
AÑO: 2022
|
Asensi-Canto A, Rodriguez-Braun E, Beltran-Videla A, Hurtado AM, Conesa-Zamora P. Effects of imipramine on cancer patients over-expressing Fascin1; description of the HITCLIF clinical trial. Front Oncol. 2023 Sep 29;13:1238464. doi: 10.3389/fonc.2023.1238464. eCollection 2023. Erratum In: Front Oncol. 2024 Apr 16;14:1405306. doi: 10.3389/fonc.2024.1405306. PubMed PMID: 37841433; PubMed Central PMCID: PMC10570506.
AÑO: 2023; IF: 3.5
|
Muta Y, Linares JF, Martinez-Ordonez A, Duran A, Cid-Diaz T, Kinoshita H, Zhang X, Han Q, Nakanishi Y, Nakanishi N, Cordes T, Arora GK, Ruiz-Martinez M, Reina-Campos M, Kasashima H, Yashiro M, Maeda K, Albaladejo-Gonzalez A, Torres-Moreno D, Garcia-Solano J, Conesa-Zamora P, Inghirami G, Metallo CM, Osborne TF, Diaz-Meco MT, Moscat J. Enhanced SREBP2-driven cholesterol biosynthesis by PKClambda/iota deficiency in intestinal epithelial cells promotes aggressive serrated tumorigenesis. Nat Commun. 2023 Dec 13;14(1):8075. doi: 10.1038/s41467-023-43690-5. PubMed PMID: 38092754; PubMed Central PMCID: PMC10719313.
AÑO: 2023; IF: 14.7
|